11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 •C 3 H 8 O 2 •H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide. Dapagliflozin Chemical Structure
⚠️ Warnings
• Dapagliflozin may cause serious kidney problems, therefore monitor kidney functions while taking the drug.
• • Consult the doctor before having any surgery, even a dental surgery, while taking medicine.
• • Get up slowly from the lying position; dapagliflozin may cause low blood pressure resulting in dizziness, lightheadedness or fainting.
• • Dapagliflozin interacts with the urine glucose test. A urine glucose test is often carried out to measure the quantity of glucose present in the urine sample of diabetes patients. The urine may test positive for glucose if the patient is taking dapagliflozin even if glucose is absent. Therefore, alternative methods have to be followed to test sugar levels in patients taking dapagliflozin.
